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Summary
In human vitiligo, cutaneous depigmentation involves cytotoxic activity of autoreactive T cells. It was
hypothesized that depigmentation can progress in the absence of regulatory T cells (Treg). The percentage of
Treg among skin infiltrating T cells was evaluated by immunoenzymatic double staining for CD3 and FoxP3,
revealing drastically reduced numbers of Treg in non-lesional, perilesional and lesional vitiligo skin. Assess-
ment of the circulating Treg pool by FACS analysis of CD4, CD25, CD127 and FoxP3 expression, and mixed
lymphocyte reactions in presence and absence of sorted Treg revealed no systemic drop in the abundance or
activity of Treg in vitiligo patients. Expression of skin homing receptors CCR4, CCR5, CCR8 and CLA was
comparable among circulating vitiligo and control Treg. Treg from either source were equally capable of
migrating towards CCR4 ligand and skin homing chemokine CCL22, yet significantly reduced expression of
CCL22 in vitiligo skin observed by immunohistochemistry may explain failure of circulating, functional Treg to
home to the skin in vitiligo. The paucity of Treg in vitiligo skin is likely crucial for perpetual anti-melanocyte
reactivity in progressive disease.
Introduction
Vitiligo is characterized by progressive loss of skin pig-
mentation. This autoimmune disorder strikes approxi-
mately 0.5–1% of the world population (Taieb et al.,
2007). Depigmentation involves progressive loss of mela-
nocytes from the basal layer of the epidermis (Le Poole
et al., 1993). Moreover, depigmentation is associated
with inflammatory infiltrates of T cells and macrophages
(Van den Wijngaard et al., 2000). In progressive disease,
the CD4 ⁄ CD8 ratio is decreased among skin-infiltrating
T cells and CD8+ T cells isolated from vitiligo skin are
cytotoxic to melanocytes (Wankowicz-Kalinska et al.,
2003). An increased number of Melanoma Antigen
Recognized by T cells (MART-1) reactive T cells has been
reported among peripheral T cells from patients with
active disease, and MART-1 reactivity as well as gp100
reactivity have likewise been demonstrated among skin-
infiltrating T cells (Ogg et al., 1998; Oyarbide-Valencia
et al., 2006; Wankowicz-Kalinska et al., 2003).
Significance
Progressive depigmentation in vitiligo involves a CTL mediated autoimmune response to melanocytes.
Although circulating CTL targeting melanosomal antigens are observed in healthy individuals, their auto-
immune impact is limited by the presence of regulatory T cells. In vitiligo patients however, CD8+ T cells
are cytotoxic towards melanocytes and Treg apparently fail to keep autoimmunity in check. Studies pre-
sented here demonstrate a significant reduction in the abundance of Treg associated with reduced CCL22
expression in patient skin, whereas functional Treg are abundant in the circulation. These studies repre-
sent an important step forward in understanding how depigmentation can progress in vitiligo patients.
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MART-1 and gp100 were first identified as target
antigens for T cells infiltrating melanoma tumors. This
raised the intriguing question, why the autoimmune
response to melanocytes effectively eliminates melano-
cytes from vitiligo skin whereas T cells infiltrating mela-
nomas fail to clear the tumor. In the past we have
proposed that a failure to suppress an ongoing immune
response to self antigens may contribute to progressive
depigmentation of the skin in vitiligo patients (Das et al.,
2001). Regulatory T cells are known to inhibit autoreac-
tivity, explaining why autoreactive T cells are present in
the circulation in the absence of autoimmune symptoms
(Baecher-Allen and Hafler, 2006). While the mechanism
of action for Treg is still not fully understood, TGF-b and
IL-10 contribute to Treg mediated immunosuppression.
TGF-b is important for imposing a regulatory phenotype
to the Treg subset and regulatory activity is dependent
on cell-cell contact (Bala and Moudgil, 2006; Joetham
et al., 2007; Zhu and Paul, 2008). Markers expressed by
Treg include FoxP3, GITR, CTLA-4 and CD25, yet only
FoxP3 expression is relatively unique to regulatory T
cells (De Boer et al., 2007). This transcription factor
affects the expression of many genes (Zheng and
Rudensky, 2007), and mutations in FoxP3 can cause
severe autoimmune disease as in IPEX (human) and
scurfy mice, supporting the importance of Treg to keep
autoreactive T cells in check (Lahl et al., 2007). An abun-
dance of Treg in tumor tissues is thought to be the root
cause of failing attempts to boost anti-tumor immunity
by powerful vaccines, and inclusion of FoxP3 as a target
antigen in vaccines was shown to boost anti-tumor
immunity (Loddenkemper et al., 2009; Nair et al., 2007).
This holds true in particular for melanoma, where self
antigens MART-1 and gp100 are among the most immu-
nogenic antigens targeted by the host anti-tumor
response (Chakraborty et al., 2004). Among circulating
Treg, a large proportion is set to home to the skin (Hira-
hara et al., 2006). Chemokine CCL1 and its receptor
CCR8 are involved in the chemoattractive process that
guides Treg to the skin, as are the combinations of
CCL5 and CCR5 and of CCL22, CCL17 and CCR4
(Colantonio et al., 2002; Hirahara et al., 2006). The cuta-
neous lymphocyte antigen (CLA) is a ligand for selectin-
like molecules PCAM and ECAM on the endothelial cell
surface in a process that determines skin homing of
lymphocytes including Treg (Iellem et al., 2003). We
have previously reported that CLA is abundantly
expressed by CD4+ and CD8+ T cells that infiltrate viti-
ligo skin (Van den Wijngaard et al., 2000).
Recent advances made in understanding the contribu-
tion of regulatory T cells to keep autoimmune responses
in check have provided incentive for the current study
on the abundance, location and activity of regulatory T
cells in vitiligo. Immuno double staining was performed
to detect and quantify FoxP3 expressing T cells infiltrat-
ing non-lesional, perilesional and lesional vitiligo skin,
comparing Treg abundance in diseased and normal
control skin. Although vitiligo manifests itself in the skin,
an important part of the etiology is defined elsewhere.
Failure to clonally delete T cells with high affinity, mela-
nocyte reactive TCR for example, occurs in the thymus
(Van den Boorn et al., 2006). Therefore, besides including
patient skin samples, the current studies describe skin
homing and T cells migrating to skin from the circulation.
In lupus eythematosus for example, an intrinsic migratory
defect may account for reduced Treg in affected tissues
(Lee et al., 2008). Multiple staining procedures were per-
formed to accurately quantify Treg by FACS analysis and
to assess their expression of skin homing receptors.
Proliferation of CD4+ ⁄ CD25) cells in the presence of
allogeneic dendritic cells, with or without added
CD4+ ⁄ CD25+ Treg maintained with CD3+ ⁄ CD28+ beads
and high dose IL-2 were used to quantify inhibition of pro-
liferation by CD4+ ⁄ CD25+ T cells. Immunohistochemistry
was followed by image analysis to compare expression
of chemoattractants CCL1, CCL17 and CCL22 in vitiligo
and control skin. Migration in response to differentially
expressed chemokine was compared for control and viti-
ligo Treg. These studies provide important novel insight
into the unique circumstances that allow for progressive
cytotoxic activity towards melanocytes by CD8+ T cells in
progressive vitiligo.
Results
Paucity of Treg in vitiligo skin tissue samples
Frozen skin sections from 3 mm biopsies double stained
for expression of CD3 and FoxP3 were used to evaluate
the abundance of Treg in human skin. Treg frequency
among infiltrating pan T cells was compared for normal
neonatal (n = 5) and adult skin (n = 5), lentigo maligna
samples (n = 4) and non-lesional, perilesional, and
lesional vitiligo skin (n ‡ 7 each). Cells were quantified
in multiple sections of each sample and the Treg frac-
tion among T cells was determined as shown in
Figure 1. A significantly reduced percentage of Treg
among infiltrating T cells was noted for non-lesional
(2.6 ± 3.5%) as well as perilesional (2.0 ± 1.6%) and
lesional vitiligo skin (7.3 ± 13.9%) as compared to
normal skin from unaffected adults with fluctuating Treg
content (46.2 ± 37.8%). The abundance of Treg was
not significantly altered when comparing adult to neona-
tal skin (42.6 ± 16.2%), or adult skin to lentigo maligna
samples (57.8 ± 42.4%). In the latter, the overall num-
ber of infiltrating T cells was elevated, with similar fre-
quencies of Treg among them. In vitiligo perilesional
skin, where the absolute numbers of T cells are
increased relative to normal control skin, this increase
was not accompanied by a relative increase in Treg.
Circulating Treg quantified
The data presented in Figure 1 initially suggested that
Treg may be sparse in vitiligo patients per se, as a
reduced frequency was observed not only in involved,
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but also in unaffected skin. Thus circulating Treg were
stained using a combination of surface markers including
CD4, and CD25 expression as well as reduced expres-
sion of CD127, followed by FoxP3 immunostaining of
permeabilized lymphocytes. The data are illustrated in
Figure 2(A), and quantified in Figure 2(B), respectively. A
trend towards increased expression of CD25 and FoxP3
and decreased expression of CD127 among CD3+CD4+
T cells in patient blood was sometimes observed. These
data support the concept that the abundance of circulat-
ing Treg is not reduced in vitiligo.
Treg function among PBMC derived cells
The abundance of circulating Treg in vitiligo patients
prompted an investigation of regulatory function. Data
in Figure 3 represent the % inhibition of proliferation
assessed for CD4+CD25+ cells sorted by FACS in a
representative experiment among three performed,
with sorted Treg stimulated by high dose IL-2 and
CD3 ⁄ CD28 coated beads and subsequently recom-
bined with the CD25) fraction of CD4+ cells in pres-
ence of allogeneic DC. The data demonstrating similar
suppression of proliferation among CD4 T cells by
sorted Treg from patient or control PBMC indicate
that there was no demonstrable functional impairment
among circulating peripheral Treg in vitiligo patients.
Thus, Treg with a functional suppressor profile circu-
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Figure 1. Paucity of Treg in vitiligo skin. Treg abundance quantified. (A) Immunostaining of all T cells (blue) and Tregs (red) was light
microscopically evaluated by two investigators. (B) The percent Treg among T cells was calculated for 4–8 samples in each group, looking for
significant differences to the % Treg found in adult normal skin by Student’s T test, with **P < 0.01, and *P < 0.05.
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Differential expression of skin homing receptors
An apparent discrepancy between abundant Treg pres-
ent in the circulation of vitiligo patients, whereas such
Treg are not found in the skin may be explained by a
failure of Treg to migrate into the skin. To differentiate
circulating Treg destined to home to the skin, FACS
staining performed included analysis of CLA expression,
as well as expression of CCR4, CCR5 and CCR8 among
Treg from control and patient samples. Since the %
Treg observed in skin was reduced regardless of depig-
mentation status as shown in Figure 1, no differentia-
tion was made between patients with active or
stationary disease for these experiments. The data
represented in Figure 4, show gating strategies (A) and
summarized data (B) representing expression of CCR4,
CCR5, CCR8 and CLA among Treg in vitiligo patients
and controls (n ‡ 7 as shown). The data demonstrate
that expression of receptors previously shown to dictate
homing of T cells and specifically Treg to the skin com-
partment is similar among the patient and control popu-
lations, although a slight trend towards increased
expression of CCR4 (at 51% of control versus 41% of
vitiligo Treg) as well as CCR5 (at 15% of control versus
10% of vitiligo Treg) is present. CLA expression in
control and vitiligo skin in double stainings with FoxP3
revealed that cells in vitiligo skin expressing the skin
























































































Figure 2. Abundance of circulating Treg
quantified by FACS analysis. (A)
Representative FACS plots for a vitiligo
and a control blood sample, with
CD4+CD25+CD127low and FoxP3+ used to
identify Treg. (B) The average percentage
of Treg among lymphocytes was
quantified and compared among control
and vitiligo samples. According to these
data, the number of Treg circulating in
patients does not support a systemic
































Figure 3. Inhibition of T cell proliferation quantified. Proliferation of
CD4+CD25) lymphocytes from patients and controls was quantified
by 3H-thymidine incorporation in the presence and absence of the
CD25+ subpopulation of CD4+ cells and allogeneic DC to stimulate
mixed lymphocyte responses, showing that circulating Treg from
vitiligo patients (n = 3) are equally capable of immunosuppression
as Treg from control individuals (n = 3). The data further support
that Treg from vitiligo patients do not display a systemic defect to
explain their paucity in vitiligo skin.
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Differential chemoattraction of Treg populations to
the skin in vitiligo
To further investigate whether reduced expression of
chemoattractants may have contributed to the paucity
of Treg within vitiligo patient skin, experiments were
focused on expression of CCL1, CCL17 and CCL22.
Expression was assessed by immunostaining for these
chemokines in n ‡ 7 samples of control and vitiligo skin
each. CCL1 (average 1120 expressing cells ⁄ mm2 for all
samples) and CCL17 (average 550 expressing
cells ⁄ mm2 for all samples) expression were similar
among immunostained sections of control and vitiligo
skin (not shown), yet CCL22 expression (in expressing
cells ⁄ mm2) was markedly reduced by 43% among
vitiligo samples compared to control skin as exemplified
in Figure 5(A, B) and quantified in (C), suggesting
that Tregs may not be as enticed to extravasate and
migrate towards the skin by the chemokine in vitiligo.
Vitiligo and control Treg responded equally well to
chemoattractant CCL22 in migration assays, as shown
in Figure 5(D), suggesting a reduction in the number of
CCL22 expressing cells within patient skin is primarily
responsible for impaired immigration.
Discussion
The presence of regulatory T cells serves to prevent
autoimmune reactivity by T cells that express receptors
reactive with self-peptides (Danese and Rutella, 2007).
Since many anti-tumor vaccines are aimed at boosting
reactivity to self-peptides, the regulatory subpopulation
of T cells can interfere with anti-tumor efficacy. In fact,
depletion of regulatory T cells has been suggested as a
means to enhance anti-tumor responses while increas-
ing risk for the development of autoimmunity as demon-
strated in human patients and associated mouse
models (Dannull et al., 2005; Jacob et al., 2009; Mahnke
et al., 2007). In mice vaccinated against melanoma
differentiation antigens including gp100 and MART-1, it
appears that Treg depletion is accompanied by depig-
mentation of the pelage (Sutmuller et al., 2001). These
data support the concept that in the absence of Treg, T
cells reactive to melanocyte differentiation antigens
demonstrate an unbridled response to melanocytes.
Research from several groups supports the involve-
ment of autoreactive, cytotoxic T cells in progressive
depigmentation of human skin, and cytotoxic T lympho-
cyte (CTL) activity can induce depigmentation in a
mouse model of human vitiligo (Das et al., 2001; Den-
man et al., 2008). The fact that melanocyte reactive
CD8+ T cells are also found in control individuals with-
out vitiligo suggests that autoimmune reactivity is kept
in check in the periphery, and that this checkpoint is
defective in vitiligo (Visseren et al., 1995). The current
data support this hypothesis.
The number of transcription factor FoxP3 expressing
T cells was significantly reduced in the skin of vitiligo
patients. Such reduction was observed not only in peri-
lesional skin (the site where regulatory activity is
needed to suppress the activity of helper and cytotoxic
T cells that are actively contributing to depigmentation)
but also in non-lesional and in lesional skin. By contrast,
the percentage of Treg in lentigo maligna lesions was


















































































































Figure 4. Skin homing marker expression among circulating Treg analyzed by FACS. (A) Representative control subject plots show sequential
gating strategies for identifying Treg, as well as CD4+FoxP3) and CD4)FoxP3) subsets among CD3+ enriched lymphocytes. These subsets
were analyzed for expression of CCR4, CCR5, CCR8 and CLA. Summarized data (B) show a similar percentage of skin homing marker
expression among patient and control Treg, and CD4)FoxP3) populations whereas CCR8 expression among non-Treg T cells was significantly
higher in vitiligo subjects (not shown). The MFI representing CCR4, CCR5, CCR8 and CLA expression was similar among patient and control
Treg.
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adult control samples, the percentage of infiltrating Treg
was highly variable as can be expected in response to
diverse environmental conditions. Depending on the pur-
pose of the study, publications frequently report on the
percentage of Treg among CD4 cells instead. Also, dif-
ferent antibodies with reduced sensitivity to FoxP3 may
be used. In studies where authors are seeking to iden-
tify an increase in Treg abundance, the use of lower
avidity antibodies can be fortuitous for that purpose. To
allow for a direct data comparison, we have chosen to
use the same antibodies in separate studies (see Le
Poole et al., 2008). Markedly different percentages of
Treg among skin T cells in vitiligo patient and control
skin were further supported in a pilot experiment to
compare the abundance of Treg among lymphocytes
emigrating from skin tissue samples on fibronectin over
the course of 2 weeks, at 15.9% from vitiligo and
83.3% from control skin. As CD8+ T cells abundantly
infiltrate lentigo maligna samples yet the proportion of
Treg is maintained, the marked reduction in the propor-
tion of Treg within vitiligo skin cannot simply be
explained by a relative increase in the influx of effector
T cells (Le Poole et al., 2002). We have previously
reported an influx of (IFN-c producing) T cells in lentigo
maligna, and the absolute number of infiltrating effector
cells is generally greater in lentigo maligna than in
vitiligo (Le Poole et al., 2002). Such a difference in the
number of effector cells between lentigo maligna and
vitiligo is perhaps not surprising, since the concentration
of target cells for the immune response is greater
in lentigo maligna than in vitiligo. In a preliminary
experiment (unpublished), quantitative PCR data from
perilesional skin of a progressive vitiligo patient com-
pared to normal control skin suggest that reduced
infiltration by Treg is accompanied by a 42-fold increase
in IFN-c transcript abundance and a 10% decrease in
IL-10 transcript abundance (b-actin transcript abundance
serving as the internal reference), favoring a proinflam-
matory versus an immunosuppressive environment.
Since an influx of effector T cells in vitiligo is not accom-
panied by an influx of Treg and in fact, resident Treg are
reduced in non-lesional (and lesional) vitiligo skin, these
data suggest that an ongoing immune response to self
antigens as observed in generalized vitiligo is not kept in
check by the appropriate immune regulatory mecha-
nisms within the skin.
In vitiligo patients, ongoing immunity is specifically
directed against melanocytes and targets melanosomal
proteins, and increased numbers of melanocyte-
reactive T cells are observed in the circulation. In vitiligo
patients, T cells with high affinity for melanosomal anti-
gens escape clonal deletion in primary lymphoid organs,
and T cell tuning may allow this process to go forward
(Van den Boorn et al., 2006). It follows that in the
absence of a regulatory component, these patients will
preferentially develop vitiligo, whereas we and others
have reported cases of coinciding vitiligo and psoriasis
as well (Al-Mutairi and Al-Doukhi, 2009; Hernandez
et al., 2008). In bona fide cases of psoriasis however,
non-functional Treg present in equal numbers are more
commonly held responsible for progressive disease
(Goodman et al., 2009). Another inflammatory skin con-
dition involving a T cell component where we have stud-
ied the involvement of Treg is condylomata. Here we
found the Treg compartment to be significantly more
abundant than in control skin, which likely contributes to
the lack of CTL efficacy in eliminating existing warts
from the skin (Le Poole et al., 2008).
The abundance of circulating Treg was similar among
vitiligo patient samples compared to controls. Indeed, if
the percentage of Treg among circulating T cells were
reduced, one would expect vitiligo patients to suffer
from generalized autoimmunity. Whereas vitiligo
patients do display an increased incidence of several

































































Figure 5. Skin homing chemokine CCL22 is markedly reduced in
vitligo patient skin. Representative images are given for control (A)
and non-lesional vitiligo (B) frozen skin immunostained for CCL22.
(C) The data reveal a significantly reduced abundance of CCL22
expressing non-lesional and intra-lesional vitiligo skin (P < 0.05).
Treg migration in response to CCL22 was also determined in
control and vitiligo samples (D). Treg abundance among migrated
CD4+ lymphocytes was measured in the absence (spontaneous
migration) or presence of CCR4 ligand CCL22. Treg migration data
were summarized showing no difference in the % Treg responding
to CCL22 among control and vitiligo CD4+ lymphocytes.
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roiditis (Kakourou et al., 2005), the majority of patients
are only affected by progressive depigmentation of the
skin. Thus it was not surprising to find that vitiligo
patients carry similar numbers of Treg in the circulation.
Treg circulating in abundance among vitiligo patients
compared to control individuals signal an attempt of the
immune system to compensate for an effector
response to self antigens, accompanying an increased
number of effector T cells previously noted for vitiligo
patients with active disease (Ogg et al., 1998). Clearly
however, these circulating Treg are incapable of keeping
the autoimmune response to melanocytes in check,
suggesting a possible defect in regulatory function.
This prompted our studies to delineate the ability of
circulating Treg to control T cell proliferation, comparing
Treg isolated from patients with those isolated from
control individuals. Our data however demonstrate, that
circulating Treg from vitiligo patients- regardless of the
activity of their disease- are functional and capable of
inhibiting helper T cell proliferation.
Observing a near complete absence of Treg in the
skin, whereas functional Treg were abundant in the cir-
culation of vitiligo patients prompted us to investigate
the expression of markers associated with Treg skin
homing. Cutaneous lymphocyte antigen (CLA), CCR4
and CCR8 have been implicated in this process, and
expression of these markers was compared among con-
trol and patient samples. In melanoma, we have
recently observed significant overexpression of CCR4
and CCR8 measured as both the number of expressing
cells and the abundance ⁄ cell among circulating Treg,
accompanied by marked expression of the ligands
within the tumor environment [(Klarquist et al., 2009
(abstract)]. By contrast, the percentage and abundance
of expression of CLA, CCR4, CCR5 and CCR8 was com-
parable among vitiligo patient and control samples
although a trend towards decreased expression of
CCR4 and CCR5 were observed among vitiligo patient
samples. Although outside the scope of the current
Treg study, another notable difference was significantly
increased expression of CCR8 among non-Treg lympho-
cytes (both CD4+ and CD8+) at P < 0.01 for each sub-
set, implicating CCR8 in infiltration of proinflammatory T
cells into vitiligo skin (not shown).
Markedly differential engagement of chemokine
CCL22 was observed, strongly suggesting that impaired
skin homing contributes to reduced regulatory activity in
the skin environment of vitiligo patients. As patient Treg
did not display an intrinsic disability to respond to
CCL22 with increased migration, the actual reduction in
the number of chemokine expressing cells within
patient skin is thought to be primarily responsible for
impaired immigration. Remaining expression of CCL22
even among patient skin samples may explain the occa-
sional detection of residual Treg in vitiligo skin. A differ-
ence in migration could not be assigned to a lack of
CCL1 or CCL17 expression in vitiligo, as patient skin
expressed similar levels of the chemokines by immuno-
histochemistry. It should be noted that the proportion of
Treg will be further influenced within the skin environ-
ment itself, possibly by differential abundance of IL-6
that can stimulate a pro-inflammatory, Th17-dominated
environment as demonstrated for psoriasic lesions
(Goodman et al., 2009).
Taken together, an inadequate number of Treg will
not be able to suppress an ongoing cytotoxic response
in vitiligo skin. Indeed, our data support that a reduced
proportion of Treg is retained in the skin of vitiligo
patients, and such reduction is accompanied by reduced
expression of CCL22. We have previously reported an
abundance of CLA expressing T cells in perilesional skin
of vitiligo patients with active disease (Van den Wijng-
aard et al., 2000), and immuno double staining of skin
sections with antibodies to FoxP3 and CLA further con-
firmed that CLA expression in vitiligo skin was not
accompanied by expression of regulatory T cell markers
(not shown). Taken together, the data can help to
explain continued cytotoxic T cell activity contributing to
progressive depigmentation. This mechanism may be
unique to vitiligo, and differs from other autoimmune
disease of the skin, where Treg are abundant in the skin
and blood, but appear to display deficient regulatory
activity (Sugiyama et al., 2005). The data support a
mechanism of reduced homing to the destination site
for Treg, allowing an active immune response to mela-
nocytes to proceed despite an abundance of functional
Treg circulating in vitiligo patients. The importance of
conditions encountered by Treg during priming in periph-
eral lymph nodes for organ-selective homing (Siewert
et al., 2007), as well as reports of temporal changes in
Treg function over time (Smyk-Pearson et al., 2008) sug-
gests that opportunities may exist to manipulate the
skin-seeking behavior of Treg in vitiligo.
Materials and methods
Patient population
For studies involving blood derived lymphocytes, a total of 30 ml of
blood was drawn from patients diagnosed with generalized vitiligo,
with either stationary or progressive disease. All patients provided
informed consent under IRB approval from Loyola University Chi-
cago. PBMC were isolated by Ficoll gradient, frozen in presence of
10% DMSO in fetal bovine serum (FBS) and stored in liquid nitro-
gen until use. Control blood was purchased from Life Source in
Chicago, IL, USA.
Four mm skin biopsies from vitiligo patients included in this
study were obtained under local anesthesia from consenting adults
for studies approved by the IRB at Loyola University Chicago. Con-
trol skin or tumor samples were obtained as otherwise discarded
tissue obtained either during circumcision, abdominoplasty,
mamma reduction or during tumor resection, respectively through
IRB approved protocols at Loyola University in conjunction with the
Departments of Surgery at the University of Chicago (IL) and the
University of Cincinnati (OH).
All patient information available and relevant to the study is sum-
marized in Table 1.
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Monoclonal antibodies
Monoclonal antibodies used for immunostaining of skin speci-
men, FACS analysis and sorting of peripheral blood samples
include antibodies to human antigens CD3 (clone F7.2.38, BD
Biosciences, San Jose, CA, USA); unlabeled or FITCCD4 (clone
RPA-T4, BD Biosciences) for immunohistology and FACS analy-
sis, respectively; FoxP3 (polyclonal rabbit IgG, Abcam, Cam-
bridge, MA, USA) for immunohistology and PEFoxP3 (clone 206D,
Biolegend, San Diego, CA, USA) for FACS analysis; CD25 (clone
2A3, BD Biosciences) for immunohistology and PE-Cy7CD25 (clone
M-A251, BD Biosciences), or PECD25 (clone 4E3, MACS Millenyi
Biotech, Auburn, CA, USA) for sorting; APC-eFlour780CD127 (clone
eBioRDR5, eBioscience, San Diego, CA, USA); PerCP-Cy5.5CCR4
(clone TG6 ⁄ CCR4, Biolegend); APCCCR8 (clone FAB1429A, R&D
Systems, Minneapolis, MN, USA); CLA (clone HECA452, Rat
IgM, BD Biosciences) for immunohistology or bioCLA(HECA452)
Table 1. (A) Patient skin biopsy samples for Treg quantification by immunohistochemistry. (B) Patient PBMC samples for FACS analysis. (C)

















Arm Male 31 8 Progressive N ⁄ A N ⁄ A Yes
Arm Male 58 31 Progressive N ⁄ A N ⁄ A Yes
Shoulder Male 60 38 Progressive N ⁄ A N ⁄ A Yes
Leg Female 50 11 Progressive N ⁄ A Tamoxifen No
Leg Female 54 29 Progressive N ⁄ A N ⁄ A Yes
Back Male 59 54 Stable N ⁄ A Naftifin No
Back Female 52 40 Stable N ⁄ A Insulin Yes
Arm Male 27 5 Progressive NB-UVB
protopic
N ⁄ A Yes
(B)
Patient gender Patient age (yr) Disease duration (yr) Disease activity Vitiligo treatment
Female 15 7 Progressive Laser + tacrolimus
Male 44 5 Progressive Laser + tacrolimus
Female 24 20 Progressive Laser + tacrolimus
Male 28 2 Stable Laser + tacrolimus
Female 34 17 Progressive Laser + tacrolimus
Male 45 18 Progressive Laser + tacrolimus
Female 55 4 Progressive Laser + tacrolimus
Female 22 13 Stable Laser + tacrolimus
Male 55 6 Regressing Laser
Female 40 11 Regressing N ⁄ A
Male 39 11 Regressing Laser + tacrolimus
Female 18 9 Stable N ⁄ A
Female 42 26 Stable N ⁄ A
(C)
Patient gender Patient age (yr) Disease duration (yr) Disease activity Vitiligo treatment
Male 36 4 Progressive Laser + tacrolimus
Female 33 30 Progressive Laser + tacrolimus
Female 48 11 Progressive Laser + tacrolimus
(D)
Biopsy site Patient gender Patient age (yr) Disease duration (yr) Disease activity Vitiligo treatment
Thorax Male 36 6 Progressive Laser + tacrolimus
Elbow Male 22 3 Progressive Laser + tacrolimus
Buttock Female 33 16 Progressive Laser + tacrolimus
Elbow Female 48 22 Progressive Laser + tacrolimus
Hip Female 40 11 Progressive Laser + tacrolimus
Elbow Female 29 16 Progressive Laser + tacrolimus
Hip Female 22 14 Progressive Laser + tacrolimus
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with Pacific Orangestreptavidin (Invitrogen, Carlsbad, CA, USA) for
FACS.
Immunohistology
Single immunostaining procedures were performed essentially as
described (Le Poole et al., 2002). Briefly, 8 lm frozen and acetone
fixed tissue sections were exposed to an antibody of interest in
empirically optimized concentrations, followed by incubations with
biotinylated rabbit anti-mouse antiserum 1:200 (DakoCytomation,
Glostrup, Denmark) and peroxidase-labeled streptavidin 1:300 (Dako-
Cytomation). Color was developed in presence of 250 lg ⁄ ml AEC
and 0.03% H2O2 and sections were counterstained in Harris modi-
fied hematoxilin (Sigma Aldrich, St. Louis, MO) before coverslipping.
Immuno double stainings were similarly performed on frozen
sections, essentially as described (Le Poole et al., 2002). Briefly,
fixed sections were exposed to a combination of two primary
antibodies of different isotypes. Washed sections were then
exposed to a combination of isotype-specific secondary antibodies
labeled either with peroxidase or alkaline phosphatase (Southern
Biotechnologies, Birmingham, AL, USA). Fast Blue BB (Sigma
Aldrich) substrate was used to develop blue color by alkaline phos-
phatase followed by AEC substrate (Sigma Aldrich) to develop red
color in presence of peroxidase.
FACS analysis
For Treg quantification and analysis of homing markers, between 2
and 5 million frozen PBMC were thawed and incubated in the pres-
ence of primary antibodies labeled as follows: PBMCs were first
negatively sorted for T cells on an EasySep magnet using a T cell
enrichment antibody cocktail (StemCell Technologies, Vancouver,
BC, Canada). Then, antibodies to PerCP-Cy5.5CCR4, FITCCCR5,
APCCCR8 and bioCLA were incubated with cells for 20 min at room
temp, followed by an additional 40 min at 4C with V450CD4,
PE-Cy7CD25 and APC-eFlour780CD127. Cells were washed twice, then
incubated with Pacific OrangeStreptavidin for 25 min at 4C. Cells
were again washed and intracellularly stained with PEFoxP3 accord-
ing to the Biolegend FoxP3 kit staining protocol. An unstained con-
trol, an FMO (FoxP3 excluded), and a fluorescence minus four
control (CCR4, CCR5, CCR8 and CLA excluded) were used as neg-
ative controls for setting gates. Multicolor analysis of between
200 000 and 1.5 million acquired events of which about 80% were
lymphocytes, was performed using the FACSCanto II (BD Bio-
sciences) configured with 405-nm solid state diode, 488-nm solid
state, and 633-nm HeNe, lasers and Flowjo analysis software (Tree-
Star, Cupertino, CA, USA).
Proliferation assays
Frozen PBMC (approximately 5 · 106 ⁄ sample) were thawed and
immunostained for FAC sorting using directly labeled antibodies to
CD4 (FITCCD4) and CD25 (PECD25). T cells were gated based on
forward ⁄ side scatter patterns. CD4+ cells without or with CD25
expression were individually sorted using our FACSAria (BD Bio-
sciences), equipped with 405, 488 and 633 lasers and is capable of
13 fluorescence detection channels, plus right and forward angle
light scatter. Sorted cells were recombined with 10 000 IU ⁄ ml of
IL-2 (Hoffman-LaRoche Inc., Nutley, NJ, USA) adding 5 · 104
beads ⁄ ml of CD3 ⁄ CD28 coated dynabeads (Dynal Biotech ASA,
Oslo, Norway) in complete media overnight. Complete media con-
sisted of IMDM (Cambex, Walkersville, MD, USA) with 10% inacti-
vated normal human AB serum (Valley Biochemical Inc,
Winchester, VA, USA) and penicillin ⁄ streptomycin ⁄ fungizone 1:100
(Mediatech, Herndon, VA, USA). Equal numbers of CD4+ ⁄ CD25)
and CD4+ ⁄ CD25+ expressing cells were combined in 96 well round
bottom plates. CD4+ ⁄ CD25) and CD4+ ⁄ CD25+ expressing cells
were plated alone or combined in equal cell numbers per well.
Cells were co-incubated for 72 h prior to addition of 30 Gy irradi-
ated mature dendritic cells, generated from adherent monocytes
cultured in AIMV (Invitrogen) in presence of 100 IU ⁄ ml of IL-4
(R&D Systems) and 400 IU ⁄ ml of GM-CSF (Berlex Laboratories,
Richmond, CA, USA) for 7 days, adding 1000 IU ⁄ ml of IFN-c (R&D
systems) for the last 48 h of culture to achieve DC maturation (Pan
et al., 2004). At the same time, 2 lCi of 3H-thymidine (25 Ci ⁄ mmol
specific activity; Amersham Biosciences, Piscataway, NJ, USA)
was added per well and cells were co-incubated for an additional
24-h period. In control wells, CD4+ ⁄ CD25)or CD4+ ⁄ CD25+ were
maintained in the same number as in the co-cultures. Cells
exposed to 3HThy were harvested using a Packard Filtermate
harvester (Packard Instruments, Meriden, CT, USA) according to
manufacturer’s instructions. Dried Unifilter 96 GF ⁄ C plates (Packard
Bioscience Company, Meriden, CT, USA) were then wet with
Microscint 20 (Packard Instruments) and radioactivity was mea-
sured by scintillation counting in a Packard Topcount Microplate
scintillation counter (Packard Instruments). Incorporation of 3H-Thy-
midine was quantified as a measure of cell proliferation and the %
inhibition of proliferation in presence of Treg was calculated as
[cpm (combined Treg and CD25) – cpm background] · 100 ⁄ [cpm
(Treg) + cpm (CD25)) – cpm background].
Migration assays
Migration assays were performed essentially as described (McFad-
den et al., 2007) and modified to measure the response of Treg to
chemoattractant CCL22. Briefly, 106 control or vitiligo PBMC
(n > 5) were added to 5 lm pore size transwell inserts of 24 well
plates (Corning Inc. Life Sciences, Lowell, MA, USA), in X-VIVO 20
media (Cambrex, Walkersville, MD, USA). Migration was assessed
in duplicate in the presence or absence of 500 ng ⁄ ml CCL22 (R&D
Systems). After 2-h incubation at 37C and 5% CO2, samples were
individually analyzed for expression of CD3, CD4, CD25 and CD127
expression by FACS to identify the Treg subpopulation among
migrated cells. Relative chemoattraction by CCL22 among both
donor groups was expressed as % Treg among CD4+ cells migrat-
ing in presence of CCL22 ⁄ % Treg migrating in absence of CCL22.
Evaluation and statistics
Immunostained slides were evaluated for infiltration of Treg by two
independent investigators. The number of FoxP3 ⁄ CD3 double
stained cells per section were counted as a percentage of the total
number of CD3 stained cells per section. Mean % of Treg
(CD3+ ⁄ FoxP3+) among T cells (CD3+) were compared among non-
lesional, perilesional and lesional vitiligo patients versus adult as well
as neonatal control skin and lentigo maligna samples, 4–8 samples
each as indicated in legends. Data were analyzed by Student’s T test
using Excel software. In functional assays, the % suppression mea-
sured as described above (1 ) proliferation of combined helper T cells
and regulatory T cells, divided by proliferation of separate helper T
cells plus regulatory T cells) was compared among vitiligo patients
(n = 3) and controls (n = 3) performing Student’s T test.
The percentage of Treg among T cells in PBMC samples ana-
lyzed by FACS was determined in five vitiligo and five control
PBMC samples. Levels of expression for skin homing receptors
and numbers of migrating Treg were FACS analyzed in terms of
percentage of T lymphocytes and the mean and median fluores-
cence intensity as well as the %. The significance of a difference
in Treg percentages was determined in a T test. Finally, the num-
ber of chemokine expressing cells per dermal area was estimated
by immunohistochemistry and image analysis. Student’s T tests
was used to evaluate reduced expression of chemokines their
receptors.
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